Active Surveillance for Prostate Cancer Triples in US Active Surveillance for Prostate Cancer Triples in US

Active surveillance or the delay of definitive treatment jumped dramatically over a 5-year study period. But an additional trend worried the study authors.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease. But new research also shows that African American men who receive the most advanced treatments for late-stage prostate cancer can live at least as long — or even longer — than their Caucasian counterparts. Why is this the case? Scientists are searching for an explanation. “The fact that African American men have better survival is of huge research interest,” said ...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
In this study, we reported that KDM5C was highly expressed in PCa and CRPC specimens, and the high expression promoted CRPC cell proliferation through repressing phosphatase and tensin homolog (PTEN) gene epigenetically. Moreover, KDM5C was transcriptionally upregulated by bromodomain-containing protein 4 (BRD4), and knockdown KDM5C sensitized the therapeutic effects of CRPC cells to the bromodomain and extraterminal (BET) inhibitor. Taken together, our study uncovers that the BRD4-KDM5C-PTEN may be a new oncogenic pathway in CRPC development, and KDM5C is a critical protein and could be an ideal target for CRPC treatment ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Authors: Livi L, Detti B, Francolini G, Terziani F, Triggiani L, D'Angelillo RM, Ingrosso G Abstract Prostate cancer is the second most frequent cancer worldwide, with a very high rate of progression despite treatment. The most aggressive form of the disease is known as castration-resistant prostate cancer, which carries a poor prognosis. We reviewed available literature regarding the combination of abiraterone acetate antihormonal drug and ablative radiation therapy for the treatment of metastatic castration-resistant prostate cancer. This dual treatment may enhance the effects of second-line hormonal therapy, as ...
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
By BISHAL GYAWALI MD, PhD Hey, I’m back! Well, you might not have noticed that my blogs were missing for the last three months but anyways, its good to be back. I was having a little time off blogs and social media as I was transitioning in my career but now I am back. Sometimes, it is very difficult to manage time for things that you must do versus things you enjoy doing, especially when these two don’t intersect. For me, these last few months the things I had to do were all bureaucratic while I couldn’t find the time for things I enjoy doing like writing these blogs. But now that we are back,...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Bishal Gyawali Cancer drugs Clinical Trials Oncology Prostate Cancer RCTs Source Type: blogs
CANCER WARNING: A common tropical disease found in certain holiday hotspots popular with British tourists could make victims more at risk of developing prostate cancer, new research has revealed.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conclusions: In summary, per the prespecified study endpoints, eribulin did not have adequate activity in chemotherapy naïve or chemotherapy pretreated patients with metastatic CRPC to support further study in this setting.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Conclusions: The model applies to high-risk RT patients; GS 9-10 remains a powerful predictor of PCSM. Comparing similar prognosis patients, CMRT is associated with improved disease-specific outcomes relative to EBRT. In poor-prognosis patients, CMRT+LTADT yields superior 10-year PCSM, potentially improving RT treatment personalization for those with HRPC.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in>90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstrated survival benefit. Of these, only radium-223 (Ra-223) specifically targets bone metastases, delays development of skeletal-related events, and improves survival. This review discusses key data from the ALSYMPCA trial, which contributed to the approval of Ra-223. Data from other trials are highlighted to provide further insight...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Review Articles Source Type: research
(University of Bradford) Prostate cancer cells change the behavior of other cells around them, including normal cells, by 'spitting out' a protein from their nucleus, new research has found.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Conclusions: Methodologically, it is valid to treat rural-urban codes directly as continuous variables in cancer studies, in addition to converting them into categories. This proposed continuous-variable method offers researchers more flexibility in their choice of analytic methods and preserves the information in the ordering. It can better inform how cancer risk varies, degree by degree, over a finer spectrum of rural-urban landscape.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Health | Hematology | Prostate Cancer | Study